Generic treprostinil, the pulmonary arterial hypertension–targeted therapy currently sold as Remodulin®, is now available for individuals using the medication delivered intravenously.

Generic treprostinil injection is approved by the U.S. Food and Drug Administration for both intravenous and subcutaneous use. However, generic treprostinil for subcutaneous use is not available at this time due to the unavailability of CADD-MS® 3 pump and subcutaneous pump supplies.

Patients prescribed generic treprostinil will only be able to use the medication intravenously until an alternative supplier for generic treprostinil subcutaneous delivery devices is identified. The manufacturer and distributor of generic treprostinil are actively seeking an alternative source for subcutaneous delivery supplies.

Patients prescribed branded Remodulin® may continue to use the medication both intravenously and subcutaneously, if they have access to the subcutaneous supplies.

The specialty pharmacies currently distributing Remodulin® and generic treprostinil are working to make transitions between brand and generic therapy as seamless as possible and to provide patients with uninterrupted access to medication. Patients with questions about generic treprostinil should contact their pulmonary hypertension (PH) care team or specialty pharmacy.

  • Accredo can be reached at 866-344-4874
  • CVS/Caremark can be reached at 877-242-2738

Additional Information on Copay Assistance for Treprostinil

Eligibility for copay assistance will vary for patients depending on whether they are prescribed Remodulin® or generic treprostinil.

  • Patients prescribed Remodulin® can contact the United Therapeutics Assist Program at 877-864-8437.
  • Patients prescribed generic treprostinil can contact Sandoz, the manufacturer of generic treprosinil. Sandoz will provide a copay card to eligible intravenous injection patients. Call the Treprostinil Injection Savings Program at 877-251-4947.
  • Patients prescribed either generic treprostinil or Remodulin® can continue to access copay grants provided by nonprofit organizations as they are available. This currently includes grants from Good Days, The Assistance Fund, The PAN Foundation and The Patient Advocate Foundation. Visit for a list of nonprofit charitable assistance funds with PH assistance programs.
  • Massachusetts law states that individuals taking a branded medication may not be provided with a manufacturer copay card if the drug has a generic equivalent approved by the FDA. PHA will continue to monitor how this law applies to those taking brand Remodulin®, particularly those using subcutaneous delivery for which a transition to generic is not currently possible.
  • California law states that individuals taking a branded medication may not be provided with a manufacturer copay card if a generic equivalent of the medication is covered by their health insurance plan in a lower-cost tier.

PHA continues to advocate for robust access to therapy that allows medical care to be driven by patients’ needs and clinicians’ judgment. PHA’s website provides information on financial assistance resources for PH therapy and some additional information that patients and health care providers may wish to discuss when considering a transition to generics.

Patients with questions about access to or the cost of treprostinil therapy should contact their specialty pharmacy or PH care team.

For more information about PHA’s Treatment Access Program, contact 301-565-3004 x749 or gro.noitaicossAHP@ecnarusnI.